BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, February 16 /PRNewswire-FirstCall/ -- Shire plc will announce full year 2005 earnings on Thursday 23 February 2006.
Results press release will be issued at: 12:00 GMT / 07:00 ET Investor conference call time: 14:00 GMT / 09:00 ET Live analyst presentation and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and live conference call at 14:00 GMT/9:00 ET. The venue for the meeting will be at the offices of Financial Dynamics Offices, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB
Please RSVP claire.rowell@fd.com for the live presentation. Live conference call: The details of the live conference call are as follows: UK dial in +44(0)1452-568-061 US / Canada dial in +1-866-224-2914 International dial in +44(0)1452-569-103 Password/Conf ID 5601288 Please RSVP ssalah@uk.shire.com for the conference call Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows: UK dial in 0845-245-5205 International dial in +44(0)1452-55-00-00 Pin code 5595703# Webcast replay www.shire.com, in the investor relations section
If you have any problems accessing this, please contact: Souheil Salah on: +44(0)1256-894160
Notes to Editors:
SHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system (CNS), gastrointestinal (GI), general products (GP) and human genetic therapies (HGT) - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shire's focused strategy is to develop and market products for specialty physicians. This approach aims to deliver increased returns and lower risks. Shire's in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
Shire plcCONTACT: For further information please contact: Investor RelationsSouheil Salah (Rest of the World) +44-1256-894-160; Heidi Wunder (NorthAmerica) +1-484-595-8970
